Mehrdad Hashemi

Prof. Mehrdad Hashemi

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
APAshkan Pouyan
Ashkan Pouyan
MGMasoud Ghorbanlo
Masoud Ghorbanlo
MEMasoud Eslami
Masoud Eslami
MJMajid Jahanshahi
Majid Jahanshahi
EZEhsan Ziaei
Ehsan Ziaei
MHMehrdad Hashemi
Mehrdad Hashemi
Glioblastoma multiforme (GBM) is the most prevalent and aggressive primary brain tumor in adults, characterized by a poor prognosis and significant resistance to existing treatments. Despite progress in therapeutic strategies, the median overall survival remains approximately 15 months. A hallmark of GBM is its intricate molecular profile, driven by disruptions in multiple signaling pathways, including PI3K/AKT/mTOR, Wnt, NF-κB, and TGF-β, critical to tumor growth, invasion, and treatment resistance. This review examines the epidemiology, molecular mechanisms, and therapeutic prospects of targeting these pathways in GBM, highlighting recent insights into pathway interactions and discovering new therapeutic targets to improve patient outcomes.

15 October 2013 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PDF file
ABAzam Bolhassani
Azam Bolhassani
SJShabnam Javanzad
Shabnam Javanzad
TSTayebeh Saleh
Tayebeh Saleh
MHMehrdad Hashemi
Mehrdad Hashemi
MAMohammad Reza Aghasadeghi
Mohammad Reza Aghasadeghi
SSSeyed Mehdi Sadat
Seyed Mehdi Sadat
Nanocarriers with various compositions and biological properties have been extensively applied for in vitro/in vivo drug and gene delivery. The family of nanocarriers includes polymeric nanoparticles, lipid-based carriers (liposomes/micelles), dendrimers, carbon nanotubes, and gold nanoparticles (nanoshells/nanocages). Among different delivery systems, polymeric carriers have several properties such as: easy to synthesize, inexpensive, biocompatible, biodegradable, non-immunogenic, non-toxic, and water soluble. In addition, cationic polymers seem to produce more stable complexes led to a more protection during cellular trafficking than cationic lipids. Nanoparticles often show significant adjuvant effects in vaccine delivery since they may be easily taken up by antigen presenting cells (APCs). Natural polymers such as polysaccharides and synthetic polymers have demonstrated great potential to form vaccine nanoparticles. The development of new adjuvants or delivery systems for DNA and protein immunization is an expanding research field. This review describes polymeric carriers especially PLGA, chitosan, and PEI as vaccine delivery systems.

1 January 2012 in Advanced Powder Technology
Verified
Journal Article
Closed access
BSBabak Sadeghi
Babak Sadeghi
FGFarshid S. Garmaroudi
Farshid S. Garmaroudi
MHMehrdad Hashemi
Mehrdad Hashemi
HNH.R. Nezhad
H.R. Nezhad
ANA. Nasrollahi
A. Nasrollahi
SASahar Ardalan
Sahar Ardalan

26 August 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MEMaliheh Entezari
Maliheh Entezari
ATAfshin Taheriazam
Afshin Taheriazam
SOSima Orouei
Sima Orouei
SFShayan Fallah
Shayan Fallah
ASArezoo Sanaei
Arezoo Sanaei
SSSaeed Samarghandian
Saeed Samarghandian
Epigenetic factors are critical regulators of biological and pathological mechanisms and they could interact with different molecular pathways. Targeting epigenetic factors has been an idea approach in disease therapy, especially cancer. Accumulating evidence has highlighted function of long non-coding RNAs (lncRNAs) as epigenetic factors in cancer initiation and development and has focused on their association with downstream targets. microRNAs (miRNAs) are the most well-known targets of lncRNAs and present review focuses on lncRNA-miRNA axis in malignancy and therapy resistance of tumors. LncRNA-miRNA regulates cell death mechanisms such as apoptosis and autophagy in cancers. This axis affects tumor metastasis via regulating EMT and MMPs. Besides, lncRNA-miRNA axis determines sensitivity of tumor cells to chemotherapy, radiotherapy and immunotherapy. Based on the studies, lncRNAs can be affected by drugs and genetic tools in cancer therapy and this may affect expression level of miRNAs as their downstream targets, leading to cancer suppression/progression. LncRNAs have both tumor-promoting and tumor-suppressor functions in cancer and this unique function of lncRNAs has complicated their implication in tumor therapy. LncRNA-miRNA axis can also affect other signaling networks in cancer such as PI3K/Akt, STAT3, Wnt/β-catenin and EZH2 among others. Notably, lncRNA/miRNA axis can be considered as a signature for diagnosis and prognosis in cancers.

7 August 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
MAMilad Ashrafizadeh
Milad Ashrafizadeh
KHKiavash Hushmandi
Kiavash Hushmandi
MHMehrdad Hashemi
Mehrdad Hashemi
MAMohammad Esmail Akbari
Mohammad Esmail Akbari
Peter KubatkaPeter Kubatka
Peter Kubatka
Ali ZarrabiAli Zarrabi
Ali Zarrabi
Bladder cancer (BC) is the 11th most common diagnosed cancer, and a number of factors including environmental and genetic ones participate in BC development. Metastasis of BC cells into neighboring and distant tissues significantly reduces overall survival of patients with this life-threatening disorder. Recently, studies have focused on revealing molecular pathways involved in metastasis of BC cells, and in this review, we focus on microRNAs (miRNAs) and their regulatory effect on epithelial-to-mesenchymal transition (EMT) mechanisms that can regulate metastasis. EMT is a vital process for migration of BC cells, and inhibition of this mechanism restricts invasion of BC cells. MiRNAs are endogenous non-coding RNAs with 19–24 nucleotides capable of regulating different cellular events, and EMT is one of them. In BC cells, miRNAs are able to both induce and/or inhibit EMT. For regulation of EMT, miRNAs affect different molecular pathways such as transforming growth factor-beta (TGF-β), Snail, Slug, ZEB1/2, CD44, NSBP1, which are, discussed in detail this review. Besides, miRNA/EMT axis can also be regulated by upstream mediators such as lncRNAs, circRNAs and targeted by diverse anti-tumor agents. These topics are also discussed here to reveal diverse molecular pathways involved in migration of BC cells and strategies to target them to develop effective therapeutics.

22 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MEMaliheh Entezari
Maliheh Entezari
MGMaryam Ghanbarirad
Maryam Ghanbarirad
ATAfshin Taheriazam
Afshin Taheriazam
MSMehrdokht Sadrkhanloo
Mehrdokht Sadrkhanloo
AZAmirhossein Zabolian
Amirhossein Zabolian
SSSaeed Samarghandian
Saeed Samarghandian
Among the different kinds of tumors threatening human life, lung cancer is one that is commonly observed in both males and females. The aggressive behavior of lung cancer and interactions occurring in tumor microenvironment enhances the malignancy of this tumor. The lung tumor cells have demonstrated capacity in developing chemo- and radio-resistance. LncRNAs are a category of non-coding RNAs that do not encode proteins, but their aberrant expression is responsible for tumor development, especially lung cancer. In the present review, we focus on both lncRNAs and exosomal lncRNAs in lung cancer, and their ability in regulating proliferation and metastasis. Cell cycle progression and molecular mechanisms related to lung cancer metastasis such as EMT and MMPs are regulated by lncRNAs. LncRNAs interact with miRNAs, STAT, Wnt, EZH2, PTEN and PI3K/Akt signaling pathways to affect progression of lung cancer cells. LncRNAs demonstrate both tumor-suppressor and tumor-promoting functions in lung cancer. They can be considered as biomarkers in lung cancer and especially exosomal lncRNAs present in body fluids are potential tools for minimally invasive diagnosis. Furthermore, we discuss regulation of lncRNAs by anti-cancer drugs and genetic tools as well as the role of these factors in therapy response of lung cancer cells.